We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Smartwatch Algorithm Detects Cardiac Arrest

By HospiMedica International staff writers
Posted on 04 Mar 2025

Out-of-hospital cardiac arrest is a critical emergency that demands immediate recognition and response; in cases of sudden, unwitnessed cardiac arrest, survival chances are extremely low. More...

One of the key indicators of cardiac arrest is the sudden loss of a pulse. The use of automated biosensors to detect unwitnessed cardiac arrest and prompt medical assistance could significantly improve survival rates, given the critical role of time in determining outcomes. However, for such systems to be effective, minimizing the false positive burden on emergency medical services is essential. Researchers have now developed an artificial intelligence (AI) system for a smartwatch that can detect signs of cardiac arrest and automatically alert emergency responders. This machine-learning algorithm, partially trained on data from patients whose hearts were intentionally stopped during medical procedures, is capable of recognizing the key indicators of cardiac arrest. While the researchers believe this system could potentially save lives, further testing is necessary to confirm its effectiveness.

The smartwatch algorithm, which leverages machine learning, was developed by Google Research (Mountain View, CA, USA), and is designed to meet performance standards suitable for large-scale use. The researchers first utilized photoplethysmography (PPG) to demonstrate that PPG measurements of peripheral pulselessness (induced by an arterial occlusion model) mirror the signal pattern of pulselessness seen in ventricular fibrillation (VF), a common arrhythmia associated with cardiac arrest. By analyzing the similarity between the PPG signals from VF and those from the occlusion model, they developed and validated a pulse loss detection algorithm using data collected from both the simulated model and real-world conditions.

Once the algorithm was developed, the researchers tested it in real-world scenarios. The results, published in Nature, showed that the system generated one unintentional emergency call per 21.67 user-years across two prospective studies. The algorithm’s sensitivity was 67.23% (with a 95% confidence interval of 64.32%–70.05%) when tested in a simulated arterial occlusion model of cardiac arrest. These findings indicate that this new technology offers a promising solution for wearable detection of sudden pulse loss while minimizing the societal impact of false alarms.


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
12-Channel ECG
CM1200B
New
Knee Arthroscopy Holder
Reison 10-353 XL
New
MR Trolley
MR9002
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: A research collaboration aims to further advance findings in human genomics research in cardiovascular diseases (Photo courtesy of 123RF)

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.